Publications

Bouazzi D, Lophaven S, Hagan PG, Botvid S, Hove LS, Prens EP, Knecht-Gurwin K, Szepietowski JC, Anaba EL, Chehad AS, Zobiri S, Serradj A, Bhuiyan MSI, Noor T, Guillem P, Parvizi MM, Saki N, Alpsoy E, Vardar C, Kanni T, Giamarellos-Bourboulis EJ, Frew JW, Al Maharbi WHA, Van Huijstee JC, Aarts P, Dewi ST, Febriana SA, Indrastuti N, Suryawati N, Pangastuti M, Adji A, Akhyar G, Nopriyati N, Hazlianda CP, Reyes-Baraona F, Matas C, Saeed H, Moodley A, Binamer Y, Kamil MAA, Jocic I, Mijuskovic Z, Mallawaarachchi K, Gangani C, Tusheva I, Boshkovski VB, Hu D, Geng S, Medianfar CE, Saunte DML, Chandran NS, Van Der Zee HH, Zouboulis CC, Benhadou F, Villumsen B, Alavi A, Ibekwe PU, Hamzavi IH, Ingram JR, Naik HB, Garg A, Boer J, Christensen R, Jemec GBE.

Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition that is associated with a prolonged diagnostic delay of approximately 7–10 years. The diagnostic delay can be attributed to various factors, including low awareness of diagnostic criteria among nondermatological healthcare professionals often leading to misdiagnosis. Screening questionnaires have been proposed for the diagnosis of HS. One such questionnaire has been validated and used in the Global Hidradenitis Suppurativa Atlas (GHiSA) Global Prevalence Study (GPS).

Bouazzi D, Nielsen SM, Hagan PGH, Botvid S, Hove LS, Prens EP, Christensen R, Jemec GBE; GHiSA Group; Knecht-Gurwin K, Szepietowski JC, Anaba EL, Chehad AS, Zobiri S, Serradj A, Bhuiyan MSI, Noor T, Guillem P, Parvizi MM, Saki N, Alpsoy E, Vardar C, Kanni T, Giamarellos-Bourboulis EJG, Frew JW, Al Maharbi WHA, Van Huijstee JC, Aarts P, Dewi ST, Febriana SA, Indrastuti N, Suryawati N, Pangastuti M, Adji A, Akhyar G, Nopriyati N, Hazlianda CP, Reyes-Baraona F, Matas C, Saeed H, Moodley A, Binamer Y, Kamil MAA, Jocic I, Mijuskovic Z, Mallawaarachchi K, Gangani C, Tusheva I, Boshkovski VB, Hu D, Geng S, Medianfar CE, Saunte DML, Chandran NS, Van der Zee HH, Zouboulis CC, Benhadou F, Villumsen B, Alavi A, Ibekwe PU, Hamzavi IH, Ingram JR, Naik HB, Garg A, Boer J.

Importance: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a substantial burden. Standardized global prevalence estimates and data on associated sociodemographic and risk factors are lacking.

Chehad AS, Zobiri S, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE , Serradj A.

Introduction: Although there has been an expansion of knowledge on HS (HS), data about the disease is largely based on Western population and no relevant African or Asian studies are available.

van Huijstee JC, van Straalen KR, Bouazzi D, Medianfar CE, Jemec GBE, Christensen R, Aarts P, Mangal RA, Erdal B, Geraedts NCT, Prens EP, van der Zee HH.

Introduction: The global prevalence of the chronic and debilitating skin disease hidradenitis suppurativa (HS) is currently unknown. Depending on the research type and the studied population, reported prevalence rates for HS range from 0.03% to 4.1%. It is crucial to investigate the global prevalence of HS using a standardized study design to facilitate earlier recognition, diagnosis, and treatment of patients. Consequently, a worldwide initiative, the Global Hidradenitis Suppurativa Atlas (GHiSA), has developed a study design to investigate the worldwide prevalence of HS in a comparable manner. In cooperation with this initiative, this study aimed to investigate the prevalence of HS in the Netherlands.

Al Maharbi W, Andersen PL, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE.

Introduction: This study, conducted as part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aimed to ascertain the prevalence of hidradenitis suppurativa (HS) in Oman and to assess its demographic distribution, adhering to standardized methodology for consistency across participating sites.

El Aissoug F, Bouazza W, Njimi H, Feghali J, Del Marmol V, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE, Benhadou F.

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent and debilitating skin disease, with a poorly understood global burden. The prevalence of HS in Belgium is not yet known. We aimed to determine the prevalence of the disease in the Belgian context and validate a screening questionnaire.

Reyes-Baraona F, Matas C, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE.

Background: The worldwide prevalence of hidradenitis suppurativa (HS) still remains unknown. In Latin America, there are scarce data regarding the prevalence of HS and in Chile, we do not have information about it. The aim of this study was to estimate the prevalence of HS in Santiago, Chile.

Kanni T, Ktena S, Leventogiannis K, Damoulari C, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE, Giamarellos-Bourboulis EJ.

Introduction: Prevalence of hidradenitis suppurativa (HS) differs between countries and the worldwide prevalence of the disease remains unknown. Prevalence of HS has never been studied in Greece. The aim of this study was to estimate the HS prevalence in Athens, the capital of Greece.

Dewi ST, Suryawati N, Indrastuti N, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE, Chandran NS, Pangastuti M, Adji A, Akhyar G, Nopriyati N, Hazlianda CP, Febriana SA.

Introduction: Studies on the prevalence of hidradenitis suppurative (HS) in Southeast Asia are scarce, and no studies have been conducted in Indonesia. This study aimed to calculate the prevalence of HS in Indonesia and validate this questionnaire in our population as part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative.

Pham J, Flora A, Kozera EK, Medianfar CE, Bouazzi D, Christensen, Jemec GBE, Frew JW.

Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.